Related Experiment Videos
Rituximab for follicular lymphoma
1Fred Hutchinson Cancer Research Center, D1-100, 1100 Fairview Avenue, North Seattle, WA 98109-1024, USA. dmaloney@fhcrc.org
Current Hematology Reports
|August 7, 2003
Summary
Rituximab, an anti-CD20 antibody, shows high response rates in follicular lymphoma. Further research is needed to optimize its use in combination with chemotherapy for better patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Rituximab is a chimeric anti-CD20 antibody used in treating CD20-positive lymphoma.
- It has a favorable toxicity profile and is effective alone or with chemotherapy.
Purpose of the Study:
- To discuss the rationale for using rituximab in follicular non-Hodgkin's lymphoma (NHL).
- To review available data on dosing, scheduling, timing, and chemotherapy combinations.
Main Methods:
- Review of clinical data and combination trials involving rituximab in follicular NHL.
- Analysis of response rates, toxicity, and minimal residual disease clearance.
Main Results:
- High response rates observed in follicular NHL (50-60% relapsed, 70% initial).
- Maintenance therapy improves responses and delays progression.
- Combination trials show feasibility and promising results, including molecular clearance of minimal residual disease.
Conclusions:
- Rituximab is a valuable treatment for follicular NHL.
- Limited randomized data and long-term results necessitate further research.
- Optimal integration into treatment protocols requires more investigation.